Table 3.
Cost‐effectiveness analysis base‐case costs and survival over a 5‐year time horizon
| Primary CEA endpoint: HF hospitalization outcomes | All‐cause hospitalization outcomes | Comprehensive patient management outcomes | ||||
|---|---|---|---|---|---|---|
| Treatment group | Control group | Treatment group | Control group | Treatment group | Control group | |
| Cumulative average cost | US$56 974 | US$ 52 149 | US$140 966 | US$133 681 | US$212 004 | US$200 360 |
| Cumulative QALYs | 2.56 | 2.16 | 2.56 | 2.16 | 2.56 | 2.16 |
| Cumulative average years survival | 3.70 | 3.47 | 3.70 | 3.47 | 3.70 | 3.47 |
| Incremental cost effectiveness ratio (US$/QALY) | US$12 262 | US$18 515 | US$29592 | |||
| Cost reduction for each patient under treatment post implant (US$/year)a | US$4443 | US$5261 | US$5296 | |||
CEA, cost‐effectiveness analysis; HF, heart failure; QALY, quality adjusted life year.
a
Cost saving per life year for the treatment group.